The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Bie, Li ^a,b   Zhao, Gang ^a   Cheng, Pui ^c   Rondeau, Gaelle ^c   Porwollik, Steffen ^c   Ju, Yan ^a   Xia, Xiao Qin ^b,c,d   McClelland, Michael ^b,c  

^a JILIN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Vaccine Research Institute of San Diego   (United States)

^d INSTITUTE OF HYDROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUB3 PROTEIN; CELL CYCLE PROTEIN 20; CENTROMERE PROTEIN E; KI 67 ANTIGEN; PROTEIN BUB1; PROTEIN BUB1B; PROTEIN MAD1L1; PROTEIN MAD2L1; PROTEIN TTK; RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN;

ARTICLE; CANCER GRADING; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE EXPRESSION; GENETIC CORRELATION; GENETIC TRANSCRIPTION; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LABELING INDEX; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREDICTION; SURVIVAL TIME; WORLD HEALTH ORGANIZATION; BIOLOGICAL MODEL; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; KAPLAN MEIER METHOD; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; TIME; TUMOR CELL LINE;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; DATABASES, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; M PHASE CELL CYCLE CHECKPOINTS; MODELS, GENETIC; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; STATISTICS, NONPARAMETRIC; TIME FACTORS; WORLD HEALTH ORGANIZATION;

EID: 80053991470     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025631     Document Type: Article

References (72)

1. Walker DG, Kaye AH, (2003) Low grade glial neoplasms. J Clin Neurosci 10: 1-13.
2. Claus EB, Black PM, (2006) Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer 106: 1358-1363.
3. DeAngelis LM, (2001) Brain tumors. N Engl J Med 344: 114-123.
4. Garside R, Pitt M, Anderson R, Rogers G, Dyer M, et al. (2007) The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 11: iii-iv, ix-221.
5. Tran B, Rosenthal MA, (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 17: 417-421.
6. Faria MH, Goncalves BP, do Patrocinio RM, de Moraes-Filho MO, Rabenhorst SH, (2006) Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology 26: 519-527.
7. Torp SH, (2002) Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neuropathol 21: 252-257.
8. Johannessen AL, Torp SH, (2006) The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 12: 143-147.
9. Paulus W, (2009) GFAP, Ki67 and IDH1: perhaps the golden triad of glioma immunohistochemistry. Acta Neuropathol 118: 603-604.
10. Torp SH, Alsaker M, (2002) Ki-67 immunoreactivity, basic fibroblastic growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. An immunohistochemical study with special reference to the reliability of different Ki-67 antibodies. Pathol Res Pract 198: 261-265.
11. Torp SH, Granli US, (2001) Proliferative activity in human glioblastomas assessed by various techniques. APMIS 109: 865-869.
12. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA, (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183.
13. Pich A, Chiusa L, Navone R, (2004) Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol 15: 1319-1329.
14. Molinie V, Longchampt E, Ouazana D, Lebret T, (2003) [Bladder tumors and molecular markers. Current status and perspectives]. Ann Pathol 23: 306-331.
15. Rindi G, D'Adda T, Froio E, Fellegara G, Bordi C, (2007) Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 18: 145-149.
16. Yoshida Y, Nakada M, Harada T, Tanaka S, Furuta T, et al. (2010) The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J Neurooncol 98: 41-47.
17. Ihmann T, Liu J, Schwabe W, Hausler P, Behnke D, et al. (2004) High-level mRNA quantification of proliferation marker pKi-67 is correlated with favorable prognosis in colorectal carcinoma. J Cancer Res Clin Oncol 130: 749-756.
18. Xia XQ, McClelland M, Porwollik S, Song W, Cong X, et al. (2009) WebArrayDB: cross-platform microarray data analysis and public data repository. Bioinformatics 25: 2425-2429.
19. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, et al. (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64: 6503-6510.
20. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, et al. (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69: 9065-9072.
21. Wong KK, Chang YM, Tsang YT, Perlaky L, Su J, et al. (2005) Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res 65: 76-84.
22. Hoyt MA, (2001) A new view of the spindle checkpoint. J Cell Biol 154: 909-911.
23. Chan GK, Liu ST, Yen TJ, (2005) Kinetochore structure and function. Trends Cell Biol 15: 589-598.
24. Hardwick KG, (2005) Checkpoint signalling: Mad2 conformers and signal propagation. Curr Biol 15: R122-124.
25. Xiao Y, Li X, Yang Y, Wang Y, Rao S, (2008) Cell cycle-dependent gene networks relevant to cancer. Progress in Natural Science 18: 945-952.
26. Weigel MT, Dowsett M, (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17: R245-262.
27. Schvartzman JM, Sotillo R, Benezra R, (2010) Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 10: 102-115.
28. Rao CV, Yamada HY, Yao Y, Dai W, (2009) Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice. Carcinogenesis 30: 1469-1474.
29. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
30. Maes L, Kalala JP, Cornelissen M, de Ridder L, (2007) Progression of astrocytomas and meningiomas: an evaluation in vitro. Cell Prolif 40: 14-23.
31. Valente V, Teixeira SA, Neder L, Okamoto OK, Oba-Shinjo SM, et al. (2009) Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol Biol 10: 17.
32. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
33. Hothorn T, Bretz F, Westfall P, (2008) Simultaneous inference in general parametric models. Biom J 50: 346-363.
34. Kamikubo K, Murase H, Murayama M, Miura K, (1986) Microcomputer-based nonlinear regression analysis of ligand-binding data: application of Akaike's information criterion. Jpn J Pharmacol 40: 342-346.
35. Lausen B, Hothorn T, Bretz F, Schumacher M, (2004) Assessment of Optimal Selected Prognostic Factors. Biometrical Journal 46: 11.
36. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, et al. (2009) A network model of a cooperative genetic landscape in brain tumors. JAMA 302: 261-275.
37. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
38. Huang da W, Sherman BT, Tan Q, Collins JR, Alvord WG, et al. (2007) The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8: R183.
39. Kanehisa M, (2002) The KEGG database. Novartis Found Symp 247: 91-101; discussion 101-103, 119-128, 244-152.
40. Rousseau A, Mokhtari K, Duyckaerts C, (2008) The 2007 WHO classification of tumors of the central nervous system- what has changed? Curr Opin Neurol 21: 720-727.
41. Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, et al. (2009) Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg 111: 203-210.
42. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, et al. (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193.
43. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, et al. (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27: 1562-1571.
44. Yamamoto Y, Matsuyama H, Chochi Y, Okuda M, Kawauchi S, et al. (2007) Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. Cancer Genet Cytogenet 174: 42-47.
45. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, et al. (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12: 405-410.
46. Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, et al. (2003) Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer-association with tumour cell proliferation. J Pathol 200: 16-22.
47. de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, et al. (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27: 1108-1115.
48. Ando K, Kakeji Y, Kitao H, Iimori M, Zhao Y, et al. (2010) High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. Cancer Sci 101: 639-645.
49. Lee YK, Choi E, Kim MA, Park PG, Park NH, et al. (2009) BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers. Br J Cancer 101: 504-510.
50. Burum-Auensen E, DeAngelis PM, Schjolberg AR, Roislien J, Mjaland O, et al. (2008) Reduced level of the spindle checkpoint protein BUB1B is associated with aneuploidy in colorectal cancers. Cell Prolif 41: 645-659.
51. Gladhaug IP, Westgaard A, Schjolberg AR, Burum-Auensen E, Pomianowska E, et al. (2010) Spindle proteins in resected pancreatic head adenocarcinomas: BubR1 is an independent prognostic factor in pancreatobiliary-type tumours. Histopathology 56: 345-355.
52. Marucci G, Morandi L, Magrini E, Farnedi A, Franceschi E, et al. (2008) Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch 453: 599-609.
53. Duchrow M, Ziemann T, Windhovel U, Bruch HP, Broll R, (2003) Colorectal carcinomas with high MIB-1 labelling indices but low pKi67 mRNA levels correlate with better prognostic outcome. Histopathology 42: 566-574.
54. Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K, Hirata Y, (2002) Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res 62: 13-17.
55. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, et al. (2007) A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 67: 10148-10158.
56. Wang YW, Zhu ZG, Liu BY, Gu QL, Li JF, et al. (2005) [Expression and clinical significance of cancer-related gene MPS-1 in gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 8: 503-506.
57. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, et al. (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol 12: 49-57.
58. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
59. Bharadwaj R, Yu H, (2004) The spindle checkpoint, aneuploidy, and cancer. Oncogene 23: 2016-2027.
60. Taylor SS, Scott MI, Holland AJ, (2004) The spindle checkpoint: a quality control mechanism which ensures accurate chromosome segregation. Chromosome Res 12: 599-616.
61. Percy MJ, Myrie KA, Neeley CK, Azim JN, Ethier SP, et al. (2000) Expression and mutational analyses of the human MAD2L1 gene in breast cancer cells. Genes Chromosomes Cancer 29: 356-362.
62. Xu L, Niesen MI, Blanck G, (2009) Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. Mol Immunol 46: 569-575.
63. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW, (2007) Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11: 25-36.
64. Kops GJ, Weaver BA, Cleveland DW, (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5: 773-785.
65. Kops GJ, Foltz DR, Cleveland DW, (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 101: 8699-8704.
66. Reis RM, Nakamura M, Masuoka J, Watanabe T, Colella S, et al. (2001) Mutation analysis of hBUB1, hBUBR1 and hBUB3 genes in glioblastomas. Acta Neuropathol 101: 297-304.
67. Olesen SH, Thykjaer T, Orntoft TF, (2001) Mitotic checkpoint genes hBUB1, hBUB1B, hBUB3 and TTK in human bladder cancer, screening for mutations and loss of heterozygosity. Carcinogenesis 22: 813-815.
68. Shigeishi H, Yokozaki H, Kuniyasu H, Nakagawa H, Ishikawa T, et al. (2001) No mutations of the Bub1 gene in human gastric carcinomas. Oncol Rep 8: 791-794.
69. Gladson CL, Prayson RA, Liu WM, (2010) The pathobiology of glioma tumors. Annu Rev Pathol 5: 33-50.
70. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, et al. (2009) Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 73: 1509-1510.
71. Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, et al. (2009) Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 19: 661-671.
72. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.